ArticleJID innovations : skin science from molecules to population health2022
Allogeneic ABCB5
Abstract read
In one paragraph
Article in JID innovations : skin science from molecules to population health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Translational development of ABCB5Stem cell research & therapy · 2022Trial
- M.O.I.S.T. Concept for the Local Therapy of Chronic Wounds: An International Update.The international journal of lower extremity wounds · 2026Review
- Dimethyl sulfoxide in cryopreserved mesenchymal stromal cell therapy products: is there a safety risk to patients?Journal of translational medicine · 2025Review
- The Differentiation and Regeneration Potential of ABCB5Journal of clinical medicine · 2025Review
- Harnessing Mesenchymal Stromal Cells for Advanced Wound Healing: A Comprehensive Review of Mechanisms and Applications.International journal of molecular sciences · 2024Review
- Systemic treatment of recessive dystrophic epidermolysis bullosa with mesenchymal stromal cells: a scoping review of the literature and conclusions for future clinical research.The Journal of dermatological treatment · 2024Article
- Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa.International journal of molecular sciences · 2024Review
- Anti-Inflammatory and Anti-(Lymph)angiogenic Properties of an ABCB5+ Limbal Mesenchymal Stem Cell Population.International journal of molecular sciences · 2024Article
- Article
- Targeting Wnt/β-catenin signaling and its interplay with TGF-β and Notch signaling pathways for the treatment of chronic wounds.Cell communication and signaling : CCS · 2024Review
- Evaluation of secretomes derived from human dermal and adipose tissue mesenchymal stem/stromal cells for skin wound healing: not as effective as cells.Stem cell research & therapy · 2024Article
- ABCB5Cytotherapy · 2023Article
- Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5Cells · 2023Article
- Clinical-grade human skin-derived ABCB5+ mesenchymal stromal cells exert anti-apoptotic and anti-inflammatory effectsFrontiers in immunology · 2023Article
- Targeting estrogen signaling and biosynthesis for aged skin repair.Frontiers in physiology · 2023Review
- Skin-Derived ABCB5International journal of molecular sciences · 2022Review
- Pooled human bone marrow-derived mesenchymal stromal cells with defined trophic factors cargo promote dermal wound healing in diabetic rats by improved vascularization and dynamic recruitment of M2-like macrophages.Frontiers in immunology · 2022Article
- Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.JCI insight · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Andreas KerstanDepartment of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0001-6483-0191
Kathrin DieterRHEACELL GmbH & Co. KG, Heidelberg, Germany.ORCID 0000-0001-6341-4161
Elke Niebergall-RothTICEBA GmbH, Heidelberg, Germany.ORCID 0000-0001-7846-3388
Ann-Kathrin DachtlerRHEACELL GmbH & Co. KG, Heidelberg, Germany.ORCID 0000-0003-3744-1937
Korinna KraftRHEACELL GmbH & Co. KG, Heidelberg, Germany.ORCID 0000-0001-9650-3988
Markus StückerDepartment of Dermatology, St. Josef Hospital Bochum, Ruhr University Bochum, Bochum, Germany.ORCID 0000-0001-5564-5285
Georg DaeschleinDepartment of Dermatology, University Medicine Greifswald, Greifswald, Germany.ORCID 0000-0002-4650-199X
Michael JüngerDepartment of Dermatology, University Medicine Greifswald, Greifswald, Germany.ORCID 0000-0002-7574-6646
Tobias GörgeDepartment of Dermatology, University Hospital Münster, Münster, Germany.ORCID 0000-0002-3631-8841
Ulrich Meyer-Pannwittpro scientia med at the Department of Clinical Research and Development, MARE Clinic, Kiel, Germany.ORCID 0000-0001-9181-6555
Cornelia Erfurt-BergeDepartment of Dermatology, University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-3722-6383
Charlotte von EngelhardtKlinische Forschung Schwerin GmbH, Schwerin, Germany.ORCID 0000-0003-1888-9015
Andreas KlareKlinische Forschung Hamburg GmbH, Hamburg, Germany.ORCID 0000-0002-8887-126X
Christiane PfeifferDepartment of Dermatology and Allergic Diseases, University Hospital, Ulm, Germany.ORCID 0000-0001-7770-168X
Jasmina EsterlechnerTICEBA GmbH, Heidelberg, Germany.ORCID 0000-0002-9840-9431
Hannes M SchröderRHEACELL GmbH & Co. KG, Heidelberg, Germany.ORCID 0000-0002-0427-5867
Martin GasserDepartment of Surgery, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0002-4987-8389
Ana M Waaga-GasserDepartment of Surgery, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0002-5587-5256
Matthias GoebelerDepartment of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0001-7095-9848
Seda BallikayaTICEBA GmbH, Heidelberg, Germany.ORCID 0000-0001-9746-0422
Samar SadeghiTICEBA GmbH, Heidelberg, Germany.ORCID 0000-0001-6846-4264
George F MurphyDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9362-5146
Dennis P OrgillDivision of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8279-7310
Natasha Y FrankDepartment of Medicine, VA Boston Healthcare System, Boston, MA, USA.ORCID 0000-0001-8196-0449
Christoph GanssRHEACELL GmbH & Co. KG, Heidelberg, Germany.ORCID 0000-0003-0396-6591
Karin Scharffetter-KochanekDepartment of Dermatology and Allergic Diseases, University Hospital, Ulm, Germany.ORCID 0000-0002-9655-685X
Markus H FrankDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1312-0488
Mark A KluthRHEACELL GmbH & Co. KG, Heidelberg, Germany.ORCID 0000-0003-0764-4645
Funding
ABCB5-positive stem cells for LSCD therapyR01EY025794 · NEI · BOSTON CHILDREN'S HOSPITAL · PI NATASHA Y FRANK, Markus H. Frank · 2016 to 2026
$6.1MMultipotent ABCB5-positive cell therapeutics for corneal diseaseR24EY028767 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI FRANK, MARKUS H., FRANK, NATASHA Y · 2018 to 2022
$5.9MNEI NIH HHS R01 EY025794NEI NIH HHS R24 EY028767
Abstract
A significant number of chronic venous ulcers (CVUs) fail to heal despite of guideline-conform standard of care. Skin-derived ABCB5
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.